Vaccination Status and Effectiveness of COVID‐19 Vaccines in Patients with Prostate and Bladder Cancer
COVID-19 vaccine in prostate and bladder cancer patients
-
Ali Nowroozi
,
Mohammad Reza Nowroozi
,
Erfan Amini
,
Seyed Ali Momeni
,
Hassan Inanloo
,
Solmaz Ohadian Moghadam
Abstract
Considering the importance of understanding COVID-19 prevalence and vaccine effectiveness in individuals dealing with bladder or prostate cancer, as well as the plausible adverse repercussions of immunization, this study was undertaken to assess the prevalence and vaccination rates of COVID-19 in this group of patient. Furthermore, the investigation seeks to evaluate potential adverse effects and the efficacy of vaccines in patients diagnosed with prostate and bladder cancer. In this cross-sectional study conducted from 2020 to 2022, we systematically extracted clinical and demographic information, COVID-19 diagnoses, clinical symptoms, and paraclinical data from the bladder and prostate cancer registry at our institution. Our analysis encompassed assessing the frequency of COVID-19 infections, vaccination rates, and the occurrence of adverse effects associated with vaccination within this specific cohort. Among the 249 enrolled patients, COVID-19 infection was confirmed in 19.4% of bladder cancer patients and 16.6% of prostate cancer patients. A substantial majority, 81% (202 patients), had received vaccination, with the Sinopharm vaccine being the preferred choice for the majority (90%). The study's outcomes reveal a vaccine efficacy of 82% in individuals with bladder cancer, while displaying a higher efficacy of 96% among patients with prostate cancer. This study provides evidence supporting the efficacy of the SARS-CoV-2 vaccine in reducing COVID-19-associated complications and mortality, as well as its high efficacy in patients with prostate and bladder cancer.
Ohadian Moghadam S. A Review on Currently Available Potential Therapeutic Options for COVID-19. International journal of general medicine. 2020;13:443-467.
2. Fillmore NR, La J, Szalat RE, et al. Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. Journal of the National Cancer Institute. 2021;113(6):691-698.
3. Giannakoulis VG, Papoutsi E, Siempos II. Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. JCO global oncology. 2020;6:799-808.
4. Tagliamento M, Agostinetto E, Bruzzone M, et al. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 2021;163:103365.
5. Fendler A, de Vries EGE, GeurtsvanKessel CH, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature reviews Clinical oncology. 2022;19(6):385-401.
6. Mekkawi R, Elkattan BA, Shablak A, Bakr M, Yassin MA, Omar NE. COVID-19 Vaccination in Cancer Patients: A Review Article. Cancer control : journal of the Moffitt Cancer Center. 2022;29:10732748221106266.
7. Greenwood E, Swanton C. Consequences of COVID-19 for cancer care—a CRUK perspective. Nature reviews Clinical oncology. 2021;18(1):3-4.
8. Cannistra SA, Haffty BG, Ballman K. Challenges Faced by Medical Journals During the COVID-19 Pandemic. J Clin Oncol. 2020:2206-2207.
9. Pinato DJ, Tabernero J, Bower M, et al. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. The Lancet Oncology. 2021;22(12):1669-1680.
10. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine. 2020;383(27):2603-2615.
11. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111.
12. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. New England Journal of Medicine. 2021;384(23):2187-2201.
13. Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2018;391(10135):2116-2127.
14. Stadtmauer EA, Sullivan KM, El Idrissi M, et al. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Human vaccines & immunotherapeutics. 2021;17(11):4144-4154.
15. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta‐analysis. Influenza and other respiratory viruses. 2013;7:72-75.
16. Thomas S, Perez J, Lockhart S, et al. 1558O COVID-19 vaccine in participants (ptcpts) with cancer: subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine. Annals of Oncology. 2021;32:S1129.
17. Oosting SF, van der Veldt AA, GeurtsvanKessel CH, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. The Lancet Oncology. 2021;22(12):1681-1691.
18. Fendler A, Au L, Shepherd ST, et al. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer. 2021;2(12):1321-1337.
19. Fendler A, Shepherd ST, Au L, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature cancer. 2021;2(12):1305-1320.
20. Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, et al. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. European journal of cancer. 2022;160:243-260.
21. Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer cell. 2021;39(8):1091-1098. e1092.
22. Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nature Microbiology. 2021;6(9):1140-1149.
23. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet infectious diseases. 2021;21(1):39-51.
24. Pinato DJ, Ferrante D, Aguilar-Company J, et al. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. European journal of cancer (Oxford, England : 1990). 2022;171:64-74.
25. Wu JT, La J, Branch-Elliman W, et al. Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study. JAMA oncology. 2022;8(2):281-286.
26. Schmidt A, Labaki C, Hsu C-Y, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Annals of oncology. 2022;33(3):340-346.
27. Lamtai H, Boutayeb S, Mrabti H, El Ghissassi I, Errihani H. Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting report. Frontiers in oncology. 2022;12:1014786
2. Fillmore NR, La J, Szalat RE, et al. Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. Journal of the National Cancer Institute. 2021;113(6):691-698.
3. Giannakoulis VG, Papoutsi E, Siempos II. Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. JCO global oncology. 2020;6:799-808.
4. Tagliamento M, Agostinetto E, Bruzzone M, et al. Mortality in adult patients with solid or hematological malignancies and SARS-CoV-2 infection with a specific focus on lung and breast cancers: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 2021;163:103365.
5. Fendler A, de Vries EGE, GeurtsvanKessel CH, et al. COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. Nature reviews Clinical oncology. 2022;19(6):385-401.
6. Mekkawi R, Elkattan BA, Shablak A, Bakr M, Yassin MA, Omar NE. COVID-19 Vaccination in Cancer Patients: A Review Article. Cancer control : journal of the Moffitt Cancer Center. 2022;29:10732748221106266.
7. Greenwood E, Swanton C. Consequences of COVID-19 for cancer care—a CRUK perspective. Nature reviews Clinical oncology. 2021;18(1):3-4.
8. Cannistra SA, Haffty BG, Ballman K. Challenges Faced by Medical Journals During the COVID-19 Pandemic. J Clin Oncol. 2020:2206-2207.
9. Pinato DJ, Tabernero J, Bower M, et al. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. The Lancet Oncology. 2021;22(12):1669-1680.
10. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England journal of medicine. 2020;383(27):2603-2615.
11. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet. 2021;397(10269):99-111.
12. Sadoff J, Gray G, Vandebosch A, et al. Safety and efficacy of single-dose Ad26. COV2. S vaccine against Covid-19. New England Journal of Medicine. 2021;384(23):2187-2201.
13. Winston DJ, Mullane KM, Cornely OA, et al. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2018;391(10135):2116-2127.
14. Stadtmauer EA, Sullivan KM, El Idrissi M, et al. Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. Human vaccines & immunotherapeutics. 2021;17(11):4144-4154.
15. Beck CR, McKenzie BC, Hashim AB, et al. Influenza vaccination for immunocompromised patients: summary of a systematic review and meta‐analysis. Influenza and other respiratory viruses. 2013;7:72-75.
16. Thomas S, Perez J, Lockhart S, et al. 1558O COVID-19 vaccine in participants (ptcpts) with cancer: subgroup analysis of efficacy/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine. Annals of Oncology. 2021;32:S1129.
17. Oosting SF, van der Veldt AA, GeurtsvanKessel CH, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. The Lancet Oncology. 2021;22(12):1681-1691.
18. Fendler A, Au L, Shepherd ST, et al. Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nature Cancer. 2021;2(12):1321-1337.
19. Fendler A, Shepherd ST, Au L, et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nature cancer. 2021;2(12):1305-1320.
20. Becerril-Gaitan A, Vaca-Cartagena BF, Ferrigno AS, et al. Immunogenicity and risk of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection after Coronavirus Disease 2019 (COVID-19) vaccination in patients with cancer: a systematic review and meta-analysis. European journal of cancer. 2022;160:243-260.
21. Addeo A, Shah PK, Bordry N, et al. Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer cell. 2021;39(8):1091-1098. e1092.
22. Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. Nature Microbiology. 2021;6(9):1140-1149.
23. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial. The Lancet infectious diseases. 2021;21(1):39-51.
24. Pinato DJ, Ferrante D, Aguilar-Company J, et al. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. European journal of cancer (Oxford, England : 1990). 2022;171:64-74.
25. Wu JT, La J, Branch-Elliman W, et al. Association of COVID-19 Vaccination With SARS-CoV-2 Infection in Patients With Cancer: A US Nationwide Veterans Affairs Study. JAMA oncology. 2022;8(2):281-286.
26. Schmidt A, Labaki C, Hsu C-Y, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Annals of oncology. 2022;33(3):340-346.
27. Lamtai H, Boutayeb S, Mrabti H, El Ghissassi I, Errihani H. Cancer patients and COVID-19 vaccination, from safety to protocol adherence: A real-life setting report. Frontiers in oncology. 2022;12:1014786
| Files | ||
| Issue | Vol 15 No 3 (2023) | |
| Section | Original Articles | |
| Keywords | ||
| COVID-19 vaccination prostate cancer bladder cancer | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Nowroozi A, Nowroozi MR, Amini E, Momeni SA, Inanloo H, Ohadian Moghadam S. Vaccination Status and Effectiveness of COVID‐19 Vaccines in Patients with Prostate and Bladder Cancer. Basic Clin Cancer Res. 2024;15(3):151-157.
